Remission of an Intracardiac Melanoma Metastasis after Tremelimumab Therapy

Tremelimumab is a fully human monoclonal antibody specific for human cytotoxic T lymphocyte-associated antigen 4. Administration of tremelimumab to patients with locally advanced and metastatic melanoma has resulted in a subset of patients with durable objective tumour regressions. Our echocardiogra...

Descripción completa

Detalles Bibliográficos
Autores principales: Spethmann, Sebastian, Trefzer, Uwe, Knebel, Fabian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2014
Materias:
Published online: February, 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3975197/
https://www.ncbi.nlm.nih.gov/pubmed/24707247
http://dx.doi.org/10.1159/000360127
_version_ 1782310102395518976
author Spethmann, Sebastian
Trefzer, Uwe
Knebel, Fabian
author_facet Spethmann, Sebastian
Trefzer, Uwe
Knebel, Fabian
author_sort Spethmann, Sebastian
collection PubMed
description Tremelimumab is a fully human monoclonal antibody specific for human cytotoxic T lymphocyte-associated antigen 4. Administration of tremelimumab to patients with locally advanced and metastatic melanoma has resulted in a subset of patients with durable objective tumour regressions. Our echocardiographic images impressively show the effects of this new antibody in a patient with cardiac metastatic malignant melanoma.
format Online
Article
Text
id pubmed-3975197
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-39751972014-04-04 Remission of an Intracardiac Melanoma Metastasis after Tremelimumab Therapy Spethmann, Sebastian Trefzer, Uwe Knebel, Fabian Case Rep Dermatol Published online: February, 2014 Tremelimumab is a fully human monoclonal antibody specific for human cytotoxic T lymphocyte-associated antigen 4. Administration of tremelimumab to patients with locally advanced and metastatic melanoma has resulted in a subset of patients with durable objective tumour regressions. Our echocardiographic images impressively show the effects of this new antibody in a patient with cardiac metastatic malignant melanoma. S. Karger AG 2014-02-15 /pmc/articles/PMC3975197/ /pubmed/24707247 http://dx.doi.org/10.1159/000360127 Text en Copyright © 2014 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions.
spellingShingle Published online: February, 2014
Spethmann, Sebastian
Trefzer, Uwe
Knebel, Fabian
Remission of an Intracardiac Melanoma Metastasis after Tremelimumab Therapy
title Remission of an Intracardiac Melanoma Metastasis after Tremelimumab Therapy
title_full Remission of an Intracardiac Melanoma Metastasis after Tremelimumab Therapy
title_fullStr Remission of an Intracardiac Melanoma Metastasis after Tremelimumab Therapy
title_full_unstemmed Remission of an Intracardiac Melanoma Metastasis after Tremelimumab Therapy
title_short Remission of an Intracardiac Melanoma Metastasis after Tremelimumab Therapy
title_sort remission of an intracardiac melanoma metastasis after tremelimumab therapy
topic Published online: February, 2014
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3975197/
https://www.ncbi.nlm.nih.gov/pubmed/24707247
http://dx.doi.org/10.1159/000360127
work_keys_str_mv AT spethmannsebastian remissionofanintracardiacmelanomametastasisaftertremelimumabtherapy
AT trefzeruwe remissionofanintracardiacmelanomametastasisaftertremelimumabtherapy
AT knebelfabian remissionofanintracardiacmelanomametastasisaftertremelimumabtherapy

Ejemplares similares